{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-004738","form_type":"8-K","ticker":"AMRX","cik":"0001723128","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2026-02-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.005532+00:00","generated_at":"2026-05-16T05:21:22.789523+00:00","sec_items":["1.01","2.03"],"event_type":"debt","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Amneal reprices $2.1B term loan, margin cut 50 bps, saving ~$11M/year","bullets":["Repricing amendment reduces interest rate margin by 50 bps to SOFR+3.00% or Base Rate+2.00%.","Total Amendment No. 2 Term Loans of ~$2.095B, including ~$134.7M new term loan.","Annualized cash interest savings estimated at ~$11 million.","Maturity unchanged at August 1, 2032.","Proceeds used to refinance existing Amendment No. 1 Term Loans."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-004738","json":"https://secwatch.observer/filing/0001628280-26-004738.json","markdown":"https://secwatch.observer/filing/0001628280-26-004738.md","text":"https://secwatch.observer/filing/0001628280-26-004738.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026004738/0001628280-26-004738-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026004738/amrx-20260202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T05:21:22.789523+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2e0ccd6688aed4cf06943e1f491a38e3ec8336fd","claim":"Amneal Pharmaceuticals, Inc. amended credit facility of $1,960,076,527.50 with JPMorgan Chase Bank, N.A. at 2.00% (for base rate) and 3.00% (for SOFR) maturing August 1, 2032.","evidence_excerpt":"on a cashless basis, its term loans outstanding immediately prior to the Repricing Amendment (the “Existing Term Loans) into new term loans with an aggregate principal amount of $1,960,076,527.50 (collectively, the “Converted Amendment No. 2 Term Loans”) and (y) the Company incurred a new term loan with an aggregate principal amount of $134,673,472.50 (the “Additional","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026004738/0001628280-26-004738-index.htm","confidence":0.95,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Principal","value":"$1,960,076,527.50"},{"label":"Counterparty","value":"JPMorgan Chase Bank, N.A."},{"label":"Rate","value":"2.00% (for base rate) and 3.00% (for SOFR)"},{"label":"Maturity","value":"August 1, 2032"},{"label":"Event","value":"amendment"}]},{"claim_id":"b05248412bad0ee00a096398493d22d5685276ff","claim":"Amneal Pharmaceuticals, Inc. incurred term loan of $134,673,472.50 with JPMorgan Chase Bank, N.A. maturing August 1, 2032.","evidence_excerpt":"the Company incurred a new term loan with an aggregate principal amount of $134,673,472.50 (the \"Additional Amendment No. 2 Term Loan\")","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026004738/0001628280-26-004738-index.htm","confidence":0.95,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"$134,673,472.50"},{"label":"Counterparty","value":"JPMorgan Chase Bank, N.A."},{"label":"Maturity","value":"August 1, 2032"},{"label":"Event","value":"incurrence"}]},{"claim_id":"04d03ebe50ac62376bc952795f09a77c9c882656","claim":"Amneal Pharmaceuticals, Inc. amended Amendment No. 2 to Term Loan Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, and the other lenders party thereto (effective 2026-02-02).","evidence_excerpt":"On February 2, 2026, Amneal Pharmaceuticals, Inc.’s (the \"Corporation\") subsidiary, Amneal Pharmaceuticals LLC (the “Company” or, the “Borrower”), and certain of the Company’s subsidiaries, as guarantors, entered into that certain Amendment No. 2 to Term Loan Credit Agreement (the “Repricing Amendment”) with JPMorgan Chase Bank, N.A., as administrative agent (the “Agent”), and the other lenders party thereto consenting to the Repricing Amendment.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1723128/000162828026004738/0001628280-26-004738-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"JPMorgan Chase Bank, N.A., as administrative agent, and the other lenders party thereto"},{"label":"Effective","value":"2026-02-02"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}